艾伯维公司 ABBV 深 沪
已收盘 02-06 16:00:00 美东时间
223.43
+4.410
+2.01%
华盛通- 最 高225.82
- 今 开218.75
- 成交量 606.71万股
- 最 低 218.5001
- 昨 收 219.02
- 总市值 3948.87亿
- 52周最高 241.44
- 市盈率 静 93.74
- 换手率 0.34%
- 52周最低 157.74
- 委 比 42.31%
- 总股本 17.67亿
- 历史最高 241.44
- 量 比 0.66
- 振 幅 3.34%
- 历史最低 -18.61
- 每 手 1
- 风险率 19.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多“瘦身术”砍成本+押注阿尔茨海默病药等新药产品线 百健(BIIB.US)利润展望强于预期
百健预测 2026 年利润将高于华尔街平均预期，这表明大幅削减成本的措施正在缓解其多发性硬化症产品销售额下降带来的影响。
02-06 20:33
美股大行评级 | 谷歌绩后获14家大行上调目标价；Arm、高通、波士顿科学、艾可菲、Snap、优步遭多家大行下调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Wave Life Sciences Ltd."超配"评级，目标价从34美元升至41美元；Piper Sandler：维持Replimune Group"超配"评级，目标价从13美元升至14美元
02-06 16:52
Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $270
Morgan Stanley analyst Terence Flynn maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $269 to $270.
02-05 21:24
BUZZ-Street View: AbbVie's strong drug pipeline sets it up well for long‑term growth
BUZZ-Street View: AbbVie's strong drug pipeline sets it up well for long‑term growth ** AbbVie ABBV.N forecast 2026 profit above Wall Street expectations on Wednesday after a Q4 beat driven by stronger‑than‑expected sales of its older immunology drug Humira ** Median PT of 31 brokerages covering the
02-05 17:59
财报速睇 | 艾伯维公司 2025财年Q4营收166.18亿美元，同比增长10.0%；归母净利润17.94亿美元，同比下滑25.0%
华盛资讯2月5日讯，艾伯维公司公布2025财年Q4业绩，公司Q4营收166.18亿美元，同比增长10.0%，归母净利润17.94亿美元，同比下滑25.0%。
02-05 14:32
AbbVie Earnings Call: New Growth Engines Take Lead
Abbvie (($ABBV)) has held its Q4 earnings call. Read on for the main highlights...
02-05 08:20
AbbVie Sees FY2026 Sales $67.000B vs $66.962B Est
AbbVie (NYSE:ABBV) is looking for FY2026 Sales of $67.000 billion vs $66.962 billion analyst estimate.
02-05 07:16
BUZZ-U.S. STOCKS ON THE MOVEx-IDEX Corp, Union Pacific, Qualcomm
BUZZ-U.S. STOCKS ON THE MOVEx-IDEX Corp, Union Pacific, Qualcomm Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500, Nasdaq and the Dow fell, as the market still grappled wi
02-05 02:42
AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth
AbbVie beat Q4 earnings and sales estimates, driven by strong Skyrizi and Rinvoq growth. The drugmaker raised its 2026 outlook despite falling Humira sales and mixed results in aesthetics.
02-05 01:38
AbbVie shares are trading lower. The company reported Q4 financial results.
AbbVie shares are trading lower. The company reported Q4 financial results.
02-04 22:04
